← Back to patent-cliff list
D-4517
Tier C — Watch / tradeD-4517
Ashvattha Therapeutics
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：VEGF
Indications (approved)：年龄相关性黄斑变性, Diabetic macular oedema
Regional status
US
Phase II
2022-08-31
EU
-
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of D-4517?
Approved indications include: 年龄相关性黄斑变性, Diabetic macular oedema.
When does the D-4517 patent expire?
No public expiry year is available for D-4517 yet; this page updates once verified.
How do I get a quote for D-4517 intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-05